Share on

Global Radioimmunoassay Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Type (Reagents and Kits, Analyzers), End-User (Hospitals, Pharmaceutical Industry and CRO, Clinical Diagnostic Laboratories), Application & Region – Industry Forecast from 2023 to 2028

Published: March, 2023
ID: 3555
Pages: 175
Formats: report pdf report excel report power bi report ppt

Radioimmunoassay Market Size (2023 to 2028)

The global radioimmunoassay market size is forecasted to be worth USD 503.7 million by 2028 from USD 423.7 million in 2023, growing at a CAGR of 3.52% during the forecast period.

Radioimmunoassay is used to measure specific proteins or other substances through agents or antibodies. Radioimmunoassay is essential in the medical field attributed to high quality, correct, related individual results, and sensitivity. A radioimmunoassay analyzer is a device that helps run tests to examine the existence and focus on the substances in the samples. Radioimmunoassay includes three factors: a pure antigen, a radiolabelled antigen, and an antibody. Advanced technologies in clinical trials in a test tube, growing demand for correct and quality results, and more reagents and kits are increasing the market.


The rising prevalence of infectious diseases and growing cancer cases worldwide are principally driving the global radioimmunoassay market growth.

Coronavirus, malaria, HIV/AIDS, and influenza are some of the most common infectious diseases. Countries like Brazil, the United States, EU5, and China had most of the population diagnosed with infectious diseases in 2019. Furthermore, as per the World Health Organization, cancer is the 2nd most dangerous disease-causing more deaths, and around 9.8 million deaths were due to cancer in 2018.

The rise in the concern about health and diagnosing various infections in the human body drives the market growth. Further, the market's development increases the number of blood donation camps and the need to determine infections in the blood. In addition, stringent rules and regulations regarding people's health safety set up growth opportunities for the radioimmunoassay market. Increasing awareness overutilization of this technique in various applications and the rise in the demand for point-of-care testing are also fuelling the market's growth.


However, the lack of skilled personnel monitoring the systems and understanding the reports degrades market demand. In addition, the cost of installing and maintaining the devices is a little high, which impedes the market growth.

Impact of COVID-19 on the global radioimmunoassay market:

As the COVID-19 pandemic unfolds, the urgent need for accurate and quick detection of SARS-CoV-2 infection remains crucial. Serological and radio-immunological testing of infected asymptomatic and symptomatic people will be in great demand. As a result, COVID-19 is expected to influence the market significantly. Due to the outbreak of the COVID-19 pandemic, the radioimmunoassay market is expected to expand significantly since these tests are widely utilized for the quick detection of this virus and are critically needed for the early identification of infected patients. As the situation has gotten more serious, immunoassay will likely play a more critical role as the urgency and complexity of the present COVID-19 scenario grows. Testing for SARS-CoV-2 is not the only requirement in caring for COVID-19 patients; quick, accurate screening and monitoring for various health problems that may develop due to COVID-19 disease management are also required.




Market Size Available

2022 to 2028

Base Year


Forecast Period

2023 to 2028

Segments Analysed

By Type, End-User, Application, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa


This research report on the global radioimmunoassay market has been segmented and sub-segmented based on type, end-user, application, and region.

Radioimmunoassay Market – By Type:

  • Reagents and Kits               
  • Analyzers 

Based on type, the reagents and kits segment is forecasted to lead the global radioimmunoassay market accounting for a significant share during the forecast period due to their durability and frequent purchase or usage, increasing support from the government.

Radioimmunoassay Market – By End User

  • Hospitals
  • Pharmaceutical Industry and CRO 
  • Clinical Diagnostic Laboratories       

Based on the end-user, the Pharmaceutical Industries segment is expected to grow over the forecast period. In the drug development and pharmaceutical industries, immunoassays are widely utilized in many critical areas of pharmaceutical analysis, including illness diagnostics, therapeutic medication monitoring, clinical pharmacokinetics, and bioequivalence investigations.

Because of the growing prevalence of cancer, autoimmune illnesses, infectious diseases, endocrine disorders, and allergy diseases worldwide, the clinical diagnosis laboratory segment is expected to grow at a healthy CAGR in the coming years.

Radioimmunoassay Market – By Application:

  • Research 
  • Clinical Diagnostics

Based on the application, the clinical diagnostic segment is likely to dominate the global radioimmunoassay market during the forecast period. RIA (Radioimmunoassay) has become one of the most widely used diagnostic techniques in clinical laboratories, with applications including determining the plasma levels of most hormones, detecting some abused substances, determining the presence of hepatitis B surface antigen in donated blood, and more.

Radioimmunoassay Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Geographically, the North American market is currently the leading regional market in the global Radioimmunoassay Market. Increasing demand for early diagnosis procedures is gearing up the market's growth to the extent. In terms of market share, North America is now the largest market for radioimmunoassay in the world. The massive size of the immunoassay market in the area is primarily attributable to the country's high-end healthcare infrastructure, immunoassay reimbursement availability, and the high incidence of chronic diseases. Furthermore, one of the primary reasons driving the regional market is the increasing investment in R&D by government agencies and pharmaceutical companies for early diagnosis and treatment. North American countries have experienced and continue to suffer a substantial economic and healthcare burden due to the high transmission rate and lack of treatment. Hospitals and diagnostic centers, for example, have made significant investments in ensuring the availability of critical equipment and medications.

Europe is following North America in holding the most significant shares in the global Radioimmunoassay Market. The growing number of campaigns, especially in rural areas, and the rise in the scale of blood banks are gearing up the growth rate of the European market. Additionally, increased radioimmunoassay products in research laboratories, pharma companies, and other laboratories and rising pharmaceutical and biotechnological companies in Europe, primarily in the United Kingdom, Germany, France, and Spain, Europe was the second-largest market for radioimmunoassay. The European Greens are essential in ensuring environmental responsibility in different parts of the continent. Using radioactive materials in RIA processes is hazardous to the environment and human health. As a result of the European Greens' deliberate attempt to replace RIA tests, the current situation has had a detrimental influence on their use in Europe.

Asia Pacific is predicted to have the highest growth rate by adopting advanced technologies and various products in the coming years. Furthermore, due to rapidly expanding healthcare infrastructure, increased spending by pharmaceutical companies on research and development to develop new molecules and capture a larger market share in this growth potential market, government initiatives, and increasing population awareness. Furthermore, with the growing medical tourism industry in developing countries, Asia Pacific is expected to have the fastest growth.

On the other hand, the Middle East and Africa are esteemed to have slight variations in the growth rate shortly.


Companies dominating the global radioimmunoassay market profiled in the report are DIAsource Immunoassays SA, Beckman Coulter, IBL International, PerkinElmer, DRG International, MP Biomedicals LLC, Cisbio, Euro Diagnostica AB, DiaSorin S.p.A, EMD Millipore, Izotop, Berthold Technologies GmbH & Co. KG and Stratec Biomedical AG.

Please wait. . . . Your request is being processed


What was the size of the radioimmunoassay market worldwide in 2021?

The global radioimmunoassay market size was worth USD 395.4 million in 2021.

What is the projected value of radioimmunoassay market by 2027?

The value of the global radioimmunoassay market is anticipated to be worth USD 486.65 million by 2027.

Which region dominated the radioimmunoassay market in 2021?

North America accounted for the largest share of the global radioimmunoassay market in 2021.

Which are the major players operating in the radioimmunoassay market?

DIAsource Immunoassays SA, Beckman Coulter, IBL International, PerkinElmer, DRG International, MP Biomedicals LLC, Cisbio, Euro Diagnostica AB, DiaSorin S.p.A, EMD Millipore, Izotop, Berthold Technologies GmbH & Co. KG and Stratec Biomedical AG are a few of the notable players in the radioimmunoassay market.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample